Jump Financial LLC Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Jump Financial LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 50,911 shares of the company's stock, valued at approximately $1,199,000. Jump Financial LLC owned 0.05% of Dyne Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Summit Investment Advisors Inc. raised its position in shares of Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares during the period. Raymond James Financial Inc. bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $2,340,000. Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $3,091,000. Wells Fargo & Company MN raised its stake in Dyne Therapeutics by 54.5% during the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after purchasing an additional 13,677 shares during the period. Finally, Trexquant Investment LP lifted its holdings in Dyne Therapeutics by 95.6% in the 4th quarter. Trexquant Investment LP now owns 125,378 shares of the company's stock worth $2,954,000 after purchasing an additional 61,288 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 over the last quarter. 20.77% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $46.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. Chardan Capital restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Piper Sandler decreased their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. JPMorgan Chase & Co. cut their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded down $0.04 during trading hours on Friday, hitting $11.07. 1,014,128 shares of the company's stock traded hands, compared to its average volume of 1,528,387. The business has a fifty day moving average price of $10.84 and a 200-day moving average price of $19.87. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $47.45. The firm has a market capitalization of $1.26 billion, a P/E ratio of -3.11 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.